ÌÇÐÄÊÓÆµ

Fisher Cherry

Cherry

Fisher Cherry

Research Assistant II

Positions

Research Assistant II
Symptom Research CAO
Internal Medicine
UT MD Anderson Cancer Center
Houston, Texas, United States

Education

BS from Texas A&M University
05/2019 - College Station, Texas, United States
PhD from ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States

Professional Statement

Austim spectrum disorders (ASD) are a heterogeneous subset of neurodevelopmental disorders characterized by restricted, repetitive behaviors and language deficits. Males are four-times more likely to be diagnosed with ASD than females. This historic sex-bias highlights the significance of the X chromosome in ASD pathogenesis. Many genes associated with ASD are critical for neruonal function and dose-sensitive. Therefore, methyl-CpG-binding protein 2 (MeCP2) is a compelling gene to model and study ASD.

Mutations in MeCP2 can lead to drastic neurodevelopmental disorders. Null mutations in MeCP2 cause Rett Syndrome, a disorder that mainly affects females. These patients experience intellectual disability, language deficits, and motor deficits. Males with Rett typically die during infancy. Duplications in MeCP2 cause MeCP2 Duplication Syndrome (MDS), a disorder that mainly affects males. These males experience seizures, intellectual disability, and motor deficits. Females with MDS typically do not have a phenotype, because they have an extreme skewing of their X chromosome inactivation in favor of the healthy allele.

Milder mutations in MeCP2 recapitulate a subset of phenotypes observed in Rett Syndrome or MDS. When MeCP2 levels were decreased by ~50%, mice displayed Rett-like phenotypes. However, when MeCP2 levels were decreased by only ~30%, mice displayed autism-related phenotypes. This was observed in an overexpression model as well. When MeCP2 levels were increased to 200% compared to wild-type, mice displayed MDS-like phenotypes. When MeCP2 levels were increased to only ~150% compared to wild-type, mice displayed autism-related phenotypes.

Mild mutations, like point mutations, in MeCP2 have been observed in patients with less severe neurodevelopmental disorders like schizophrenia or autism. These patients are commonly male. I hypothesize that similar mutations in non-coding regions, like the promoter, will increase or decrease MeCP2 levels in a manner that less severe than what is observed in patients with Rett Syndrome or MDS, and this mild alteration in MeCP2 levels will confer autism-related phenotypes. Since MeCP2 is an X-linked gene, I also hypothesize that males are more vulnerable to these mild, non-coding mutations.

Selected Publications

  • AC Das, JM Nichols, CV Crelli, L Liu,, R Vichare, HV Pham, CM Gaffney, FR Cherry, PM Grace, AJ Shepherd, JM Janjic. " " Sci Rep. 2024 Aug 16;
    Pubmed PMID: .

Funding

Graduate School of Biomedical Sciences Busch-80 Scholarship
ÌÇÐÄÊÓÆµ of Medicine
T32 139534-03
(07/31/2023 - 07/30/2025)
National Institutes of Health

to edit your profile